- Bestsellers
- Alcoholism
- COVID-19
- Allergy
- Anti Fungal
- Alzheimers
- Anti Viral
- Anti-Depressants
- Anti-Inflammatory
- Antibacterial
- Antiparasitic
- Antibiotics
- Arthritis
- Asthma
- Birth Control
- Blood Pressure
- Cancer
- Cardiovascular
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Drop
- Gastro Health
- General Health
- Hair Loss
- Hepatitis C Virus (HCV)
- HIV
- Hormones
- Men's ED Packs
- Men's Health
- Mental Illness
- Motion Sickness
- Muscle Relaxant
- Pain Relief
- Parkinson’s Disease
- Veterinary Medicines
- Quit Smoking
- Vitamins
- Skin Care
- Sleeping Aids
- Weight Loss
- Women's Health
Generic Rapamycin ( Sirolimus )
Rapamycin (sirolimus) is an immunosuppressant agent indicated for the prophylaxis of organ rejection in kidney transplant recipients. It is used in combination with cyclosporine and corticosteroids, or with corticosteroids alone after cyclosporine withdrawal in selected patients. Sirolimus works by binding to the intracellular protein FKBP‑12, forming a complex that inhibits the mammalian target of rapamycin (mTOR), a kinase that regulates cell cycle progression. This inhibition blocks T‑lymphocyte activation and proliferation in response to cytokine and growth factor stimulation, thereby suppressing the immune response against the transplanted organ. Sirolimus is not a calcineurin inhibitor and is not associated with nephrotoxicity at usual therapeutic doses.
Usual adult dose: For de novo kidney transplant recipients, a loading dose of 3 mg/m² is given on the first day after transplantation, followed by a maintenance dose of 1 mg once daily. For patients converted from calcineurin inhibitors after transplant, a loading dose of 2 to 3 mg is given, followed by 1 mg once daily, with subsequent dose adjustments based on whole blood trough concentrations. The 1 mg tablet is the standard maintenance strength. Sirolimus must be taken consistently with or without food to minimize variability in absorption; grapefruit juice must be avoided. The tablets should be swallowed whole. Therapeutic drug monitoring is essential; target trough levels are generally 5 to 15 ng/mL depending on the regimen and time post‑transplant. Dose adjustments are made by the transplant team based on trough levels, renal function, and tolerability. If a dose is missed, the patient should take it as soon as remembered unless it is almost time for the next dose; two doses must not be taken at the same time.
Dosage form: Oral tablets: 1 mg (white to off‑white, triangular‑shaped, film‑coated). Also available as 0.5 mg and 2 mg tablets, and as an oral solution (1 mg/mL) for patients unable to take tablets. The 1 mg tablet is commonly used for once‑daily maintenance therapy.
Onset of action: Immunosuppressive activity begins within hours of the first dose because of rapid absorption; peak whole blood concentrations occur approximately 1 to 2 hours after oral administration. However, steady‑state levels and full therapeutic immunosuppression take 5 to 7 days of continuous daily dosing to establish, which is why a loading dose is used in de novo transplantation.
Duration of action: The elimination half‑life of sirolimus is approximately 62 hours, which is much longer than calcineurin inhibitors. Once‑daily dosing maintains immunosuppression throughout a 24‑hour interval. After discontinuation, the drug is cleared slowly over several days to weeks, so trough levels should be checked and the dose adjusted only by the transplant team.
Alcohol recommendation: Alcohol should be avoided or strictly limited during sirolimus therapy. Alcohol may increase the risk of gastrointestinal irritation and hepatic dysfunction, and can interact with immunosuppressants by worsening lipid abnormalities, which are already a known side effect of sirolimus. Patients should discuss any alcohol use with their transplant specialist.
Most common side effects: Hyperlipidemia (hypercholesterolemia and hypertriglyceridemia), thrombocytopenia, leukopenia, anemia, peripheral edema, hypertension, diarrhea, nausea, headache, and arthralgia. Hyperlipidemia is frequent and may require dietary modification or lipid‑lowering therapy; fasting lipids should be monitored at baseline and periodically. Myelosuppression is dose‑dependent and usually reversible; complete blood counts should be checked regularly, especially in the first months. Sirolimus is associated with impaired wound healing and an increased risk of lymphocele and wound dehiscence; therefore, the medication may be withheld before elective surgery. Delayed graft function and renal function should be monitored when sirolimus is combined with cyclosporine, as this combination may increase calcineurin inhibitor nephrotoxicity. Rarely, interstitial lung disease and hepatic artery thrombosis in liver transplant recipients have been reported. Sirolimus is not recommended in liver or lung transplant recipients because of an increased risk of hepatic artery thrombosis and bronchial anastomotic dehiscence, respectively. Live vaccines should be avoided. Women of childbearing potential must use effective contraception during treatment and for 12 weeks after the last dose, as sirolimus may cause fetal harm. Rapamycin is available only by prescription and must be prescribed and monitored by a transplant specialist or healthcare professional experienced in immunosuppressive therapy.
Would you like to try Rapamycin (Sirolimus) without a prescription?
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
